Drug Trial Radar · NCT03531320
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Last checked: Nov 20, 2026Latest source record: Nov 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Aug 6, 2018
Primary completion
Dec 28, 2020
Study completion Dec 29, 2020
Sponsor
- Lead sponsor
- InnoPharmax Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI) cancer. Part 2: Dose-Expansion Phase (Phase 2) The primary objective is to assess the safety and tolerability of D07001 softgel in patients who have achieved stable disease or better following first line chemotherapy or combined chemoradiotherapy (CCRT) for unresectable metastatic or locally advanced biliary tract cancer (BTC)
Conditions
- Gastrointestinal Cancer
- Biliary Tract Cancer
Interventions
D07001-softgel capsulesDrug
Active Ingredient:Gemcitabine hydrochloride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Establish the Maximum Tolerated Dose (MTD)Time frame: During Cycle 1 of treatment (each cycle is 21 days) for each subject
- Part 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)Time frame: From date of informed consent to 30-day follow-up visit for each subject, an average of 10 months
- Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study DrugTime frame: First dose through last dose for each subject, an average of 8 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
China Medical University Hospital
Taichung, Taiwan
National Cheng-Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.